Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes

Yun Gyoo Lee, Inho Kim, Sung Soo Yoon, Seonyang Park, June Won Cheong, Yoo Hong Min, Jeong Ok Lee, Soo Mee Bang, Hyeon Gyu Yi, Chul Soo Kim, Yong Park, Byung Soo Kim, Yeung Chul Mun, Chu Myoung Seong, Jinny Park, Jae Hoon Lee, Sung Yong Kim, Hong Ghi Lee, Yeo Kyeoung Kim, Hyeoung Joon Kim

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The present study aimed to directly compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic syndromes (MDS). We compared the overall response rate (ORR) (complete responses, partial responses, marrow complete responses, and haematological improvements), overall survival (OS), event-free survival (EFS), time to leukaemic transformation, and adverse outcomes between azacitidine and decitabine. To minimize the effects of treatment selection bias in this observational study, adjustments were made using the propensity-score matching method. Among 300 patients, 203 were treated with azacitidine and 97 with decitabine. Propensity-score matching yielded 97 patient pairs. In the propensity-matched cohort, there were no significant differences between the azacitidine and decitabine groups regarding ORR (44% vs. 52%), OS (26 vs. 22·9 months), EFS (7·7 vs. 7·0 months), and rate of leukaemic transformation (16% vs. 22% at 1 year). In patients ≥65 years of age, survival was significantly better in the azacitidine group (P = 0·017). Patients who received decitabine experienced more frequent episodes of grade 3 or 4 cytopenia and infectious episodes. We found that azacitidine and decitabine showed comparable efficacy. Among patients ≥65 years of age, survival was significantly better in the azacitidine group (ClinicalTrials.gov Identifier: NCT01409070).

Original languageEnglish
Pages (from-to)339-347
Number of pages9
JournalBritish Journal of Haematology
Volume161
Issue number3
DOIs
Publication statusPublished - 2013 May 1

Fingerprint

decitabine
Azacitidine
Myelodysplastic Syndromes
Propensity Score
Survival
Therapeutics
Disease-Free Survival
Selection Bias
Observational Studies

Keywords

  • Azacitidine
  • Comparison
  • Decitabine
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Hematology

Cite this

Lee, Y. G., Kim, I., Yoon, S. S., Park, S., Cheong, J. W., Min, Y. H., ... Kim, H. J. (2013). Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. British Journal of Haematology, 161(3), 339-347. https://doi.org/10.1111/bjh.12256

Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. / Lee, Yun Gyoo; Kim, Inho; Yoon, Sung Soo; Park, Seonyang; Cheong, June Won; Min, Yoo Hong; Lee, Jeong Ok; Bang, Soo Mee; Yi, Hyeon Gyu; Kim, Chul Soo; Park, Yong; Kim, Byung Soo; Mun, Yeung Chul; Seong, Chu Myoung; Park, Jinny; Lee, Jae Hoon; Kim, Sung Yong; Lee, Hong Ghi; Kim, Yeo Kyeoung; Kim, Hyeoung Joon.

In: British Journal of Haematology, Vol. 161, No. 3, 01.05.2013, p. 339-347.

Research output: Contribution to journalArticle

Lee, YG, Kim, I, Yoon, SS, Park, S, Cheong, JW, Min, YH, Lee, JO, Bang, SM, Yi, HG, Kim, CS, Park, Y, Kim, BS, Mun, YC, Seong, CM, Park, J, Lee, JH, Kim, SY, Lee, HG, Kim, YK & Kim, HJ 2013, 'Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes', British Journal of Haematology, vol. 161, no. 3, pp. 339-347. https://doi.org/10.1111/bjh.12256
Lee, Yun Gyoo ; Kim, Inho ; Yoon, Sung Soo ; Park, Seonyang ; Cheong, June Won ; Min, Yoo Hong ; Lee, Jeong Ok ; Bang, Soo Mee ; Yi, Hyeon Gyu ; Kim, Chul Soo ; Park, Yong ; Kim, Byung Soo ; Mun, Yeung Chul ; Seong, Chu Myoung ; Park, Jinny ; Lee, Jae Hoon ; Kim, Sung Yong ; Lee, Hong Ghi ; Kim, Yeo Kyeoung ; Kim, Hyeoung Joon. / Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. In: British Journal of Haematology. 2013 ; Vol. 161, No. 3. pp. 339-347.
@article{77066e3b10a243a8ba9eb407e401ddef,
title = "Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes",
abstract = "The present study aimed to directly compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic syndromes (MDS). We compared the overall response rate (ORR) (complete responses, partial responses, marrow complete responses, and haematological improvements), overall survival (OS), event-free survival (EFS), time to leukaemic transformation, and adverse outcomes between azacitidine and decitabine. To minimize the effects of treatment selection bias in this observational study, adjustments were made using the propensity-score matching method. Among 300 patients, 203 were treated with azacitidine and 97 with decitabine. Propensity-score matching yielded 97 patient pairs. In the propensity-matched cohort, there were no significant differences between the azacitidine and decitabine groups regarding ORR (44{\%} vs. 52{\%}), OS (26 vs. 22·9 months), EFS (7·7 vs. 7·0 months), and rate of leukaemic transformation (16{\%} vs. 22{\%} at 1 year). In patients ≥65 years of age, survival was significantly better in the azacitidine group (P = 0·017). Patients who received decitabine experienced more frequent episodes of grade 3 or 4 cytopenia and infectious episodes. We found that azacitidine and decitabine showed comparable efficacy. Among patients ≥65 years of age, survival was significantly better in the azacitidine group (ClinicalTrials.gov Identifier: NCT01409070).",
keywords = "Azacitidine, Comparison, Decitabine, Myelodysplastic syndromes",
author = "Lee, {Yun Gyoo} and Inho Kim and Yoon, {Sung Soo} and Seonyang Park and Cheong, {June Won} and Min, {Yoo Hong} and Lee, {Jeong Ok} and Bang, {Soo Mee} and Yi, {Hyeon Gyu} and Kim, {Chul Soo} and Yong Park and Kim, {Byung Soo} and Mun, {Yeung Chul} and Seong, {Chu Myoung} and Jinny Park and Lee, {Jae Hoon} and Kim, {Sung Yong} and Lee, {Hong Ghi} and Kim, {Yeo Kyeoung} and Kim, {Hyeoung Joon}",
year = "2013",
month = "5",
day = "1",
doi = "10.1111/bjh.12256",
language = "English",
volume = "161",
pages = "339--347",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes

AU - Lee, Yun Gyoo

AU - Kim, Inho

AU - Yoon, Sung Soo

AU - Park, Seonyang

AU - Cheong, June Won

AU - Min, Yoo Hong

AU - Lee, Jeong Ok

AU - Bang, Soo Mee

AU - Yi, Hyeon Gyu

AU - Kim, Chul Soo

AU - Park, Yong

AU - Kim, Byung Soo

AU - Mun, Yeung Chul

AU - Seong, Chu Myoung

AU - Park, Jinny

AU - Lee, Jae Hoon

AU - Kim, Sung Yong

AU - Lee, Hong Ghi

AU - Kim, Yeo Kyeoung

AU - Kim, Hyeoung Joon

PY - 2013/5/1

Y1 - 2013/5/1

N2 - The present study aimed to directly compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic syndromes (MDS). We compared the overall response rate (ORR) (complete responses, partial responses, marrow complete responses, and haematological improvements), overall survival (OS), event-free survival (EFS), time to leukaemic transformation, and adverse outcomes between azacitidine and decitabine. To minimize the effects of treatment selection bias in this observational study, adjustments were made using the propensity-score matching method. Among 300 patients, 203 were treated with azacitidine and 97 with decitabine. Propensity-score matching yielded 97 patient pairs. In the propensity-matched cohort, there were no significant differences between the azacitidine and decitabine groups regarding ORR (44% vs. 52%), OS (26 vs. 22·9 months), EFS (7·7 vs. 7·0 months), and rate of leukaemic transformation (16% vs. 22% at 1 year). In patients ≥65 years of age, survival was significantly better in the azacitidine group (P = 0·017). Patients who received decitabine experienced more frequent episodes of grade 3 or 4 cytopenia and infectious episodes. We found that azacitidine and decitabine showed comparable efficacy. Among patients ≥65 years of age, survival was significantly better in the azacitidine group (ClinicalTrials.gov Identifier: NCT01409070).

AB - The present study aimed to directly compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic syndromes (MDS). We compared the overall response rate (ORR) (complete responses, partial responses, marrow complete responses, and haematological improvements), overall survival (OS), event-free survival (EFS), time to leukaemic transformation, and adverse outcomes between azacitidine and decitabine. To minimize the effects of treatment selection bias in this observational study, adjustments were made using the propensity-score matching method. Among 300 patients, 203 were treated with azacitidine and 97 with decitabine. Propensity-score matching yielded 97 patient pairs. In the propensity-matched cohort, there were no significant differences between the azacitidine and decitabine groups regarding ORR (44% vs. 52%), OS (26 vs. 22·9 months), EFS (7·7 vs. 7·0 months), and rate of leukaemic transformation (16% vs. 22% at 1 year). In patients ≥65 years of age, survival was significantly better in the azacitidine group (P = 0·017). Patients who received decitabine experienced more frequent episodes of grade 3 or 4 cytopenia and infectious episodes. We found that azacitidine and decitabine showed comparable efficacy. Among patients ≥65 years of age, survival was significantly better in the azacitidine group (ClinicalTrials.gov Identifier: NCT01409070).

KW - Azacitidine

KW - Comparison

KW - Decitabine

KW - Myelodysplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=84876168826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876168826&partnerID=8YFLogxK

U2 - 10.1111/bjh.12256

DO - 10.1111/bjh.12256

M3 - Article

VL - 161

SP - 339

EP - 347

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -